C4 Therapeutics is sawing off another part of its solely owned pipeline, this time ending work on its clinical-stage BRAF ...

The Massachusetts biotech will focus its efforts and resources into cemsidomide, an oral drug candidate being trialed for ...

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

Nicole A. Cipriani, explores the clinical relevance of the BRAF p.V600E mutation in papillary thyroid carcinoma and its potential role in guiding treatment decisions.

While BRAF inhibitors (such as vemurafenib) initially halt tumor growth, many tumors quickly adapt and survive treatment, leading to therapy failure. Unlike traditional resistance driven by ...

LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, ...

Compared to acquired mutations driving resistance to early generation BRAF inhibitors, no new mutations in MAPK pathway genes were found following plixorafenib treatment, supporting the dimer ...

In this third installment of MedPage Today's virtual roundtable series on pediatric low-grade glioma, moderator Jason Fangusaro, MD, of Emory University School of Medicine in Atlanta, is joined ...

Their findings suggest that GSK3β becomes increasingly active in cancer cells during treatment, helping them survive and adapt despite ongoing therapy with BRAF inhibitors. Melanoma is a type of ...